Gene expression profiles in CML non-responders
Research type
Research Study
Full title
Detecting expression profiles associated with resistance to tyrosine kinase inhibitors in chronic myeloid leukaemia patients without detectable tyrosine kinase domain mutations, using transcriptomics
IRAS ID
230634
Contact name
Mark Watson
Contact email
Sponsor organisation
Sheffield Childrens Hospital
Duration of Study in the UK
0 years, 2 months, 1 days
Research summary
Chronic myeloid leukaemia (CML) is a haematological malignancy primarily driven by the fusion oncogene BCR-ABL1, resulting in a constitutively expressed tyrosine kinase. CML is treated very effectively by the tyrosine kinase inhibitors (TKIs) resulting in almost undetectable levels of disease. However, some patients show resistance to first line treatment, requiring second and third generation TKIs. Such resistance is due to the presence of tyrosine kinase domain (TKD) mutations, however TKDs do not appear to be present in all patients who do not respond to treatment.
The aim of this project is to utilise gene expression arrays to identify transcriptomic profiles associated with resistance to TKIs in the absence of a demonstrable TKD mutation. The presence of such profiles may allow for a more targeted approach to treatment, if non-responders can be identified earlier in the disease management pathway. Being able to predict those that will not respond to first line treatment will allow for better stratification of patients.
REC name
Yorkshire & The Humber - South Yorkshire Research Ethics Committee
REC reference
17/YH/0302
Date of REC Opinion
13 Sep 2017
REC opinion
Favourable Opinion